About Luye Pharma Group Ltd.
Luye Pharma Group Ltd., founded in 1994 and headquartered in Yantai, Shandong, is an international pharmaceutical group listed in Hong Kong (2186) dedicated to developing, producing and selling innovative medicines. Its identity is built on advanced drug delivery technologies.
Its R&D platforms span long-acting and extended-release technology, liposomes and targeted delivery, transdermal drug delivery systems and new compounds, complemented by the biologics capability of its Boan Biotech subsidiary in antibodies and cell therapy. Its products include risperidone and paliperidone microsphere injectables, the paclitaxel liposome Lipusu and rivastigmine and rotigotine transdermal patches.
The group markets more than thirty products in over eighty countries and regions, with R&D centres in China, the United States and Europe and eight GMP-compliant manufacturing sites. Its main therapeutic areas are oncology, central nervous system, cardiovascular and alimentary tract and metabolism.
Its R&D platforms span long-acting and extended-release technology, liposomes and targeted delivery, transdermal drug delivery systems and new compounds, complemented by the biologics capability of its Boan Biotech subsidiary in antibodies and cell therapy. Its products include risperidone and paliperidone microsphere injectables, the paclitaxel liposome Lipusu and rivastigmine and rotigotine transdermal patches.
The group markets more than thirty products in over eighty countries and regions, with R&D centres in China, the United States and Europe and eight GMP-compliant manufacturing sites. Its main therapeutic areas are oncology, central nervous system, cardiovascular and alimentary tract and metabolism.